Moderna Stuns Wall Street With Surprise Profit, Raises Outlook
Moderna (MRNA) jumps as Q3 earnings swing to a surprise profit of $0.38/share on strong global vaccine sales and cost cuts.
Stocks · News reference
Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average rising 0.61% to 51,778.04
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Moderna (MRNA) jumps as Q3 earnings swing to a surprise profit of $0.38/share on strong global vaccine sales and cost cuts.
Moderna reported quarterly earnings of $0.38 per share, significantly beating the consensus estimate of a loss of $1.1 per share, with a 134.55% earnings surprise. The company posted revenues of $1.31 billion, surpassing estimates by 47.73%. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Moderna shares have gained 718.8% year-to-date, substantially outperforming the S&P 500's 7.4% gain.
U.S. stocks rose, Nasdaq gained ~400 points. Moderna jumped 9.1% on strong Q3 results and higher FY26 guidance; other stocks rallied on results and deals.
Moderna reported a surprise profitable quarter with $1.31B in revenue (29% YoY growth) and $0.38 EPS, defying analyst expectations of a loss. The company raised full-year guidance and ended with $8.1-8.3B in cash. Its cancer vaccine with Merck showed strong Phase 3 results, reducing melanoma recurrence risk by 42%, while the stock has surged 720% in 2026. However, risks include COVID vaccine sales volatility and significant optimism already priced into the stock.
Oklo stock rises after Q3 revenue beats estimates, Aurora reactor construction advances and a new manufacturing deal supports expansion.
Oklo Inc. released its financial results for the third quarter ended September 30, 2026, and provided a business update on its advanced nuclear technology projects.